Australia - English - Department of Health (Therapeutic Goods Administration)

biocelect pty ltd - japanese encephalitis virus, quantity: 4 pfu - injection, powder for - excipient ingredients: albumin; mannitol; glutamic acid; histidine; sodium chloride; potassium hydroxide; lactose monohydrate; water for injections - imojev is indicated for prophylaxis of japanese encephalitis caused by the japanese encephalitis virus, in individuals from 9 months of age and over.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - japanese encephalitis virus, quantity: 6 agu - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate; water for injections - jespect is indicated for active immunisation against japanese encephalitis (je) virus for persons 18 years of age and older. jespect should be considered for use in persons who plan to reside in or travel to areas where je is endemic (common) or epidemic (seasonal), especially during the transmission season. jespect is indicated for persons who work with je virus in laboratories and in industry.

European Union - English - EMA (European Medicines Agency)

valneva austria gmbh - japanese-encephalitis virus, inactivated (attenuated strain sa14-14-2 grown in vero cells) - encephalitis, japanese; immunization - vaccines - ixiaro is indicated for active immunisation against japanese encephalitis in adults, adolescents, children and infants aged two months and older.ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.

United States - English - NLM (National Library of Medicine)

valneva scotland ltd. - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (unii: dz854i04ze) (japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) - unii:dz854i04ze) - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) 6 ug in 0.5 ml - ixiaro is a vaccine indicated for the prevention of disease caused by japanese encephalitis virus (jev). ixiaro is approved for use in individuals 2 months of age and older. severe allergic reaction (e.g., anaphylaxis) after a previous dose of ixiaro, any other japanese encephalitis virus vaccine, or any component of ixiaro, including protamine sulfate, is a contraindication to administration of ixiaro [see description (11)]. alternatively, because of uncertainty as to which component of the vaccine may be responsible, individuals with a history of severe allergic reaction to another japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with ixiaro is considered. pregnancy category b. reproduction studies have been performed in female rats at doses approximately 300-fold excess relative to the projected human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm to the fetus due to ixiaro. there are, however, no adequate and well‑controlled

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - japanese encephalitis vaccine 6 units - suspension for injection - 6 u/dose - active: japanese encephalitis vaccine 6 units excipient: aluminium hydroxide gel dibasic sodium phosphate monobasic potassium phosphate sodium chloride - jespect® is indicated for active immunisation against japanese encephalitis (je) virus for persons 18 years of age and older. jespect® should be considered for use in persons who plan to reside in or travel to areas where je is endemic (common) or epidemic (seasonal), especially during the transmission season. jespect® is indicated for persons who work with je virus in laboratories and in industry.

New Zealand - English - Ministry for Primary Industries

new zealand bloodstock ltd - japanese encephalitis virus - japanese encephalitis virus 0 vaccine - vaccine

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - live, attenuated, recombinant -

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: zuellig pharma corporation; distributor: zuellig pharma corporation - japanese encephalitis vaccine (live, attenuated) - powder for suspension for injection (sc) - formulation: after reconstitution, one dose (0.5 ml) contains 4.0-5.8 log plaque forming units (pfu) live, attenuated, recombinant japanese encephalitis virus.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

farmaco healthcare sdn. bhd. - live-attenuated japanese encephalitis virus (seed strain: sa 14-14-2) -

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - tick-borne encephalitis virus (inactivated) neudoerfl - suspension for injection in pre-filled syringe - 0.25 millilitre(s) - encephalitis vaccines; encephalitis, tick borne, inactivated, whole virus - encephalitis vaccines - it is indicated for the active (prophylactic) immunization of children aged from 1 year to 15 years against tick-borne encephalitis (tbe).